Explore the Agenda
7:30 am Morning Check-in & Coffee
8:20 am Program Director’s Opening Remarks
8:25 am Chair’s Opening Remarks
Looking At Competitive Outliers: Strategies for True Pipeline Progression from Early Promise to Clinical Proof of Concept through Lessons Emerging from Phase II & III RLT Studies
Despite the RLT field going through a period of rapid growth and innovation, with the market projected to reach over $14 billion by 2032, the last FDA approved therapy occurred almost 4 years ago. Considering the increasing competition in the market there is a question at the forefront of the industries mind – how do we move beyond phase one studies?
Join the first plenary session to see how industry leaders are doing just that.
8:30 am Scientific Advisory Board Fireside Chat: Radiopharmaceuticals in 2026- Landscape Signals, Inflection Points & What Comes Next?
Step inside a candid, forward-looking conversation with the field’s scientific leaders as they dissect what the data has – and hasn’t – told us about radiopharmaceuticals heading into 2026. Challenge
assumptions, explore inflection points, and put your questions directly to the experts shaping the next wave of innovation, regulation, and clinical design
- Which scientific assumptions about radiopharmaceutical behavior have held up under clinical data through 2026 – and which are now clearly incomplete or wrong?
- Are current pharmacokinetic and dosimetry models sufficiently predictive for decision-making, or are we still over-relying on empirical iteration in the clinic?
- What is needed in the field to continue investment and movement?
- What lessons from recent late-stage programs should be influencing how we design first-in-human studies today?
- Does existing regulatory paradigms adequately reflect the unique risk–benefit calculus of radiopharmaceuticals, or is misalignment now a rate-limiting step?
- Which manufacturing and supply-chain constraints are a fundamentally scientific problem – and which require more infrastructural changes?
- Looking ahead, what scientific bottleneck is most likely to determine winners and failures in radiopharmaceuticals beyond 2026?
9:00 am Session Reserved for PSI CRO
9:30 am Transforming Outcomes in Advanced SSTR-Positive Neuroendocrine Tumors: Phase 3 Progress with ^225Ac-DOTATATE Targeted Alpha Therapy
- Improving antitumor efficacy in β-PRRT–refractory NETs through high-LET-particle cytotoxicity
- Addressing dosimetry, radionuclide supply, and daughter isotope redistribution to optimize safety
- Expanding clinical accessibility via novel chelators, combination strategies, and optimized radiolabeling protocols
10:00 am Speed Networking – How does it work?
10:05 am Speed Networking
A prime opportunity to make the most of in-person networking and forge new connections with an expanding community of experts in the radiopharmaceutical field. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the 5th Targeted Radiopharmaceuticals Summit US.
10:45 am Morning Break & Networking
Optimizing your Drug from Discovery Phase: Key Targeting Moiety Engineering for Optimal Biodistribution & Half-life Whilst Minimizing Toxicity
11:00 am Lowering Off‑Target Uptake in Biologic Radiopharmaceuticals through Protein Engineering
- Utilizing intracellular trapping to prevent isotope and daughter escape, strengthening tumor retention
- Providing a mechanistic basis for safer and more effective application of alpha emitters
- Leveraging tumor-specific metabolic activity to achieve sufficient radioconjugate accumulation
11:30 am Optimizing the Biodistribution & Pharmacokinetics of Abdera’s ROVEr Platform to Maximize Tumor Uptake
- Designing a modular platform for optimizing pharmacokinetics to maximize tumor uptake while minimizing off-target exposure
- Expanding the options available to engineer new functionality into antibody-based targeted radiotherapies
- Enabling protein and linker engineering that tunes BioD and clearance for new targets
12:00 pm Preclinical Evaluation & Optimization of a Multi-Specific Targeting Peptide for Radioligand Therapy
- Scientific rationale for TwoStep Therapeutics’ multi-specific targeting agent (PIP) and how it enables broad applicability across solid tumors
- Comparing the data from a single vs multitargeted approach to highlight the rationale of multi-specific targeting
- Optimization of the PIP-Radio Conjugate for RLT: approach and learnings to improve biodistribution and tumor retention
12:30 pm Lunch & Networking
Discovering Better RLT Binders & Targets Faster: Screening Strategies to Overcome Hit ID Bottlenecks
1:30 pm Navigating Next-Generation Chelators to Differentiate & Advance Radiotherapeutics
- Presenting targeted radiopharmaceuticals discovery platform designed for a wide range of targets; outlining the importance of chelator choice to achieve optimal stability, specific activity, and pharmacokinetics.
- Showcasing data for novel bifunctional “tunable” chelators superior to DOTA and Macropa
- Introducing advanced methodologies for in-depth preclinical characterization of radiopharmaceuticals using HPLC- ICP/MS techniques
2:00 pm Accelerating Radioligand Discovery: Leveraging In Silico Screening & AI to Overcome Lead-Finding Bottlenecks
- Exploring what works and what does not in existing AI and in silico platforms for faster target and hit identification
- Comparing approaches across modalities, from small molecules to antibodies, to see what drives pipeline success
- Identifying the real bottlenecks in hit discovery and optimization, so screens yield more actionable leads
2:30 pm Session Choice
Afternoon Break & Poster Presentation Session
Take this opportunity to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships whilst exploring the latest in radioligand therapy development and research advancements within poster presentations.
For more information on poster submissions, please contact info@hansonwade.com
OR
Afternoon Break & 1-2-1 Partnering Session
A brand-new additional networking opportunity – One-to-one partnering meetings arranged via the conference app, allowing you to identify, schedule, and meet potential RLT collaborators in a targeted and time-efficient way.
Powering Precision Oncology with Late-Stage Phase 2 & Phase 3 Radiopharmaceutical Evidence
As radiopharmaceuticals move into later-stage development, the strength and relevance of Phase 2 and Phase 3 evidence increasingly determine their impact in precision oncology. This session will focus on how well-designed late-stage clinical data can support regulatory approval and clinical adoption – ultimately translating targeted radiation into meaningful patient benefit.
3:30 pm The Roadmap from Phase I to Phase III: Standardizing Theranostic Protocols for Clinical Trial Success
- Developing adaptable protocols that ensure safe, reproducible procedures across early- and late-stage trials
- Optimizing multidisciplinary workflows to support patient care, regulatory compliance, and staff training at every phase
- Enabling consistent and high-quality data generation to accelerate trial progression and clinical adoption
4:00 pm Introducing the Safety & Efficacy of CONV01-Alpha for the Treatment of Men with Advanced Prostate Cancer
- Delivering a potent alpha-emitting payload directly to PSMA-expressing mCRPC cells via an antibody platform, improving tumor specificity while minimizing exposure to healthy tissues
- Avoiding key limitations of small-molecule alpha radiotherapies, including rapid renal clearance and non-specific uptake, through controlled antibody-based biodistribution
- Enabling a differentiated safety–efficacy balance in advanced prostate cancer by combining high-energy alpha radiation with precise PSMA targeting
4:30 pm Beyond Systemic RLT: Phase 2 Evidence of Local Alpha Therapy to Prevent Peritoneal Recurrence
- Limitations of systemic radioligand therapies in addressing microscopic peritoneal disease
- Scientific and clinical rationale for intraperitoneal delivery of alpha-emitting radiopharmaceuticals
- Development strategy for Radspherin® targeting prevention of peritoneal recurrence following surgery
5:00 pm Powering Precision Oncology at Scale: Radiopharmaceutical Evidence Driving Approval and Adoption
- Summarizing Phase 2/3 outcomes demonstrating meaningful efficacy, safety, and theranostic patient selection – clarifying registrational strategies that validate targeted therapies and inform precision oncology practice
- Showing how real world evidence, evolving trial designs, and clearer regulatory pathways shape endpoints, diagnostics, and post marketing plans to accelerate approvals and guiding commercial execution
- Outlining solutions for isotope supply, manufacturing scale up, and just in time logistics to build resilient, GMP aligned networks that lower COGS and expand patient access across new indications
5:20 pm Chair’s Closing Remarks
5:40 pm End of Scientific Program Day One
5:45 pm Targeted Connections Drinks Reception
Network with your fellow RLT experts over a drink at our Evening Drinks Reception – expand on your connections & continue your conversations in a relaxed atmosphere.